Top 5 stories on injectable HIV treatment and PrEP from CROI 2024
Long-acting injectables can be a good option for people with adherence challenges
Top 5 HIV treatment stories from CROI 2024
Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment
Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment
Once-weekly antiretrovirals on the horizon
Injectable treatment just as effective as standard HIV combination in Africa
Long-acting injectables may be better than daily pills for people with adherence challenges
Cabotegravir levels lower than trials in real-world study, but no increase in viral rebound